Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Bluebird Bio Buys Gene-Editing Firm
by Ann M. Thayer
July 7, 2014
| A version of this story appeared in
Volume 92, Issue 27
Bluebird Bio, a gene therapy company based in Cambridge, Mass., has acquired Precision Genome Engineering (Pregenen). Bluebird paid about $16 million in stock and assumed about $5 million in debt to buy the Seattle-based firm. It could pay up to another $135 million if therapies identified through Pregenen’s technology meet development milestones. Pregenen uses DNA-cleaving homing endonucleases and related enzymes for gene editing and targeted modification of cells for therapeutic purposes. Bluebird focuses on severe genetic and orphan diseases; it has two clinical-stage programs under way.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X